PROGRAMME



Kazuki Tobita Page 1/2

Wednesday, June 07, 2023 **SPEAKERS' CORNER** Update on innovations, clinical trials and new data - treatment of femoropopliteal PAD I - part II 14:30 - 15:30 MODERATOR Ralf Langhoff MODERATOR Yann Gouëffic Clinical impact of additional Cilostazol treatment on restenosis risk following Heparin-bonded stent 14:30 - 14:35 graft implantation: Sub-analysis from the Viabahn stent-graft placement for femoropopliteal diseases requiring endovascular therapy (VANQUISH) study Kazuki Tobita Intravascular Lithotripsy for the treatment of common femoral artery calcification: Results from the 14:35 - 14:40 disrupt PAD III observational study Konstantinos Stavroulakis 3 years comparable clinical outcome for Trans-Atlantic Inter-Society Consensus (TASC) D 14:40 - 14:45 femoropopliteal occlusion: Endovascular vs bypass surgery Yin Ting Rosanna Chow Midterm results of the Supera stent for the treatment of multi-level occlusive atherosclerotic artery 14:45 - 14:50 disease The influence of diabetes, lesion length, calcification, and bailout stenting on CD-TLR, safety, 14:50 - 14:55 patency, ABI and RCC in the BIOPACT RCT trial Endovascular and surgical revascularization techniques in long femoropopliteal lesions – 2-year 14:55 - 15:00 results of a patient-level meta analysis Serdar Farhan Comparing 12-months results of the CE and IDE studies and the PATHFINDER post-market registry 15:00 - 15:05 evaluating the safety and efficacy of the Auryon laser atherectomy system Marianne Brodmann The 1-year result of PRESTO for TASC D femoropopliteal artery lesion: Single centre experience in 15:05 - 15:10 Hong Kong Skyi Yin Chun Pang

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME



Kazuki Tobita Page 2/2

Wednesday, June 07, 2023

15:10 – 15:30 Discussion and conclusion

Ralf Langhoff Yann Gouëffic

We are asking all faculty members to strictly respect the given time limits.